ImmunoPrecise Antibodies Secures $8-10M Partnership for Novel Cancer Therapeutics Development

ImmunoPrecise Antibodies, Antibody-Drug Conjugates (ADCs), bispecific antibodies, cancer treatment, AI-driven discovery, B-cell Select™ technology

Viking Therapeutics Signs $150 Million Manufacturing Deal with CordenPharma for Obesity Drug VK2735

Viking Therapeutics, CordenPharma, VK2735, Obesity drug, GLP-1/GIP dual agonist, Contract manufacturing, API production, Fill/finish capacity, Subcutaneous and oral formulations